Skip to main content
OpenTrials
Completed

NCT Number: NCT03262272

Evaluation of Biocompatibility and Performances of 4 Dialyzers in Different Mode Treatments

Prospective multicenter randomized cross-over study Number of patients : 32 (8 patients per group) Obtain objectives data to advise each hemodialyzer according to dialysis treatment and patient profile.

To evaluate the different hemodialyzers and judge their extraction performances in HD and post HDF.

Evaluation of the biocompatibility of the hemodialyzers and the patients' inflammatory status.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Medical devices studied :

  • Leoceed 21HX, hemodialyzer, High permeability PS membrane 2,1 m² , made by Nx Stage in Germany
  • Polypure 22S, hemodialyzer, High permeability PS membrane 2,2 m² , made by Allmed in Germany
  • VIE 21A hemodialyzer, High permeability PS membrane 2,1 m² coated in vitamin E, made by Asahi Kasei Medical in Japan
  • Rexsys 27H, hemodialyzer , High permeability PES membrane 2,7 m² , made by Medica in Italia

These hemodialyzers are EC marked and are used in their own indications.

Schema

Details of the cross-over plan :

8 patients will be treated successively with the 4 hemodialyzers. Patients will be treated with the dialyzer "test" for the two first sessions of the week. During the last dialysis session of each week, only their usual dialyzer will be used as wash-out. A randomization will define the order of use of the dialyzers in the 4 centers. This order will be identical in a center.

Number of patients :

32 (8 patients per center (4 centers))

Duration :

One week per dialyzer

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient with chronic kidney disease dialyzed for at least one month and treated with the treatment mode that we will test
  • Patient using post-dilution HDF mode have to use EuDIAL volume guidelines (20-22L minimum)
  • Patient treated before with high permeability membrane
  • Patient with vascular access allowing a blood flow rate with a minimum of 300 mL/min
  • Patient treated with a high surface area dialyzer ≥ 1,8 m²
  • Patient covered by the social French health organism
  • Patient informed of the study goals and having signed the informed consent

Exclusion criteria

  • Patient with a vascular access not allowing a blood flow rate minimum of 300 mL/min
  • Patient with a fast progressive chronic disease
  • Patient with an uncontrolled anemia
  • Patient refusing to sign the informed consent
  • Pregnant or nursing patient
  • Pediatric patient
  • Patient under tutorship

Treatment and study plan

VIE A Hemodialyzer

Device

polysulfon membrane coated with vitamin E

Rexsys 27H hemodialyzer

Device

polyethersulfon membrane with large surface area : 2,7m²

Leoceed 21HX hemodialyzer

Device

polyslfon membrane with gamma sterilization

Polypure 22S+ hemodialyzer

Device

polysulfon membrane with steam sterilization

Primary outcomes

  1. Evaluation of middle molecules extraction

    Time frame: one week per dialyzer per patient

    Measurements of β 2 microglobulin (11,8kDa), myoglobin (17kDa), Beta Trace (21kDa), Free immunoglobulin light chains Kappa (23kDa), myostatin (40kDa), glycoprotein orosomucoïd (44kDa)

Secondary outcomes

  1. Extraction of uremic toxins

    Time frame: one week per dialyzer per patient

    • Urea
    • Creatinin
    • inorganic phosphates
  2. Biocompatibility assessment

    Time frame: one week per dialyzer per patient

    • Anaphylatoxins (C3a, C5a) during the session (T0, T15, Tend)
    • TNF-α and IL-6 (T0 et Tend)
  3. Monitoring of Nutrition status

    Time frame: one week per dialyzer per patient

    Quantification of the albumin loss in the used dialysate (1 center) during the middle session of the week for each dialyzer tested per patient, i.e 4 times/patient.

    2 analysis modalities will be used: " pull and push " syringe Plastipak BD 50mL or collection of the whole dialysate in a 200 L tank

    Dosage Albumin et pre-albumin before dialysis session

  4. Handling of the devices

    Time frame: one week per dialyzer per patient

    • Evaluation of the priming and recovery for each dialysis session
  5. Dialysis adequacy evaluation

    Time frame: one week per dialyzer per patient

    Calculation of KT/V

  6. Session tolerance

    Time frame: one week per dialyzer per patient

    All secondary troubles will be noted: cramps, nauseas, hypotension…

  7. Parameters inflammation

    Time frame: one week per dialyzer per patient

    CRP (mg/l)

  8. Parameters inflammation

    Time frame: one week per dialyzer per patient

    • Calcul of PINI = [CRP(mg/l) x Orosomucoïd (mg/l)] / [Albumin(g/l) x Pre-albumin(mg/l)]

Sponsors and collaborators

Lead sponsor

Hemotech

Industry

Registry information

Official study title

Evaluation of Dialyzers' Biocompatibility and Performances Compared in Different Dialysis Treatments : Conventional Hemodialysis and Post-dilution Hemodialfiltration

Acronym: BIOMODAL

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Aug 25, 2017
Registry last updated
Feb 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.